CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arcturus Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arcturus Therapeutics Holdings Inc
10628 Science Center Dr Ste 250
Phone: (858) 900-2660p:858 900-2660 SAN DIEGO, CA  92121-1132  United States Ticker: ADHDADHD
Business Summary
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Peter C.Farrell 82 5/27/2018 5/27/2018
President, Chief Executive Officer, Director Joseph E.Payne 52 3/1/2013 3/1/2013
Chief Financial Officer, Director Andrew H.Sassine 59 9/1/2019 5/1/2018
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Arcturus Therapeutics, Inc. 10628 Science Center Drive San Diego CA United States

Business Names
Business Name
ADHD
ARCT
Arcturus Therapeutics Asia Pte. Ltd.
Arcturus Therapeutics Europe B.V.
Arcturus Therapeutics, Inc.

General Information
Number of Employees: 174 (As of 12/31/2024)
Outstanding Shares: 27,119,823 (As of 3/4/2025)
Shareholders: 9
Stock Exchange: NASD
Federal Tax Id: 461981974
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025